Wayne Macfadden M.D. is a Clinical Psychiatrist with over two decades of experience in psychiatry and pharmacology. Wayne Macfadden, M.D. has co-authored several research studies on the effectiveness of various drugs in treating disorders, including schizophrenia and bipolar depression.
Recently, the FDA approved Spravato (esketamine) for use as an antidepressant, the first such drug approved in many years. Below are answers to some of the most common questions about the drug:
Q: What are the side effects of Spravato?
A: Common side effects include sedation, dizziness, and dissociation.
Q: How quickly does Spravato start to affect symptoms of depression?
A: In clinical trials, improvement in symptoms was demonstrated at four weeks when administered with an oral antidepressant.
Q: How long will treatment last?
A: The duration of the treatment will vary. The healthcare provider will help their patient determine how long to use Spravato based on how well the patient responds to the treatment.
